Xeris Biopharma Holdings, Inc./$XERS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Ticker

$XERS
Sector
Primary listing

Employees

394

XERS Metrics

BasicAdvanced
$1.5B
-
-$0.21
0.86
-

Bulls say / Bears say

Total revenue in Q2 2025 rose 48.8% year-over-year to a record $71.5 million, driven by a 135.7% increase in Recorlev® net revenue, underscoring strong commercial momentum (Business Wire).
Xeris raised its full-year 2025 revenue guidance to $280–$290 million—up from $260–$275 million—reflecting confidence in sustained product demand and long-term growth prospects (Business Wire).
The FDA approval and upcoming launch of Gvoke VialDx™ in partnership with American Regent expands Xeris’s portfolio into diagnostic applications, diversifying revenue streams beyond endocrine therapies (Investing.com).
Keveyis® net revenue fell approximately 12.5% year-over-year in Q2 2025 as product shipments declined, signaling challenges in sustaining growth for Xeris’s legacy rare disease therapy (Business Wire).
Xeris ended Q4 2024 with $71.6 million in cash—having generated just $2 million during the quarter—raising concerns over its near-term liquidity given ongoing R&D and commercialization investments (Business Wire).
Two directors resigned in March 2025 and the board will shrink to eight members after the Annual Meeting, potentially disrupting governance continuity during a critical growth phase (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XERS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Xeris Biopharma Holdings, Inc. stock | $XERS Share Price | Lightyear